Date:7/23/2009

June 30, ----------------- 2009 2008 ---- ---- Operating activities: Net loss $(1,537) $(8,149) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 12,811 8,449 In-process research and development - 4,176 Stock-based compensation 12,999 10,298 NeoDisc technology costs - - Other non-cash adjustments 3,328 312 Noncontrolling interest (683) - Changes in operating assets and liabilities: Accounts receivable 2,221 (5,044) Inventory (19,939) (16,496) Prepaid expenses and other current assets (694) (1,707) Accounts payable and accrued liabilities (288) 3,361 Accrued payroll and related expenses (652) (1,282) ---- ------ Net cash used in operating activities 7,566 (6,082) Investing activities: Cash paid for acquisitions - (6,256) Cash paid for Cervitech acquisition (24,055) - Investment in Progentix (10,000) - Acquisition related milestone payments (10,000) - Purchases of property and equipment (12,440) (25,686) Purchases of short-term marketable securities (12,004)
'/>"/>

SOURCE NuVasive, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. NuVasive to Present at the 8th Annual Needham Life Sciences Conference
2. NuVasive to Present at the 2009 William Blair Growth Stock Conference
3. NuVasive to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference
4. NuVasive Reports First Quarter 2009 Financial Results
5. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
6. NuVasive Announces Conference Call and Webcast of First Quarter 2009 Results
7. NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
8. NuVasive to Present at Barclays Capital Global Healthcare Conference
9. NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
10. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
11. NuVasive to Present at Canaccord Adams Musculoskeletal Conference